Skip to main
SGHT

Sight Sciences (SGHT) Stock Forecast & Price Target

Sight Sciences (SGHT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Sight Sciences Inc. is well-positioned for revenue growth, primarily due to anticipated market share gains in the minimally invasive glaucoma surgery (MIGS) sector and accelerated adoption of its TearCare System. The company’s Surgical Glaucoma business is expected to sustain growth in alignment with the overall MIGS market, reinforcing its key revenue drivers. Furthermore, the upward revisions in earnings per share (EPS) projections for 2025 and 2026 indicate improved financial health and progress towards profitability.

Bears say

Sight Sciences Inc. faces a challenging outlook, as it reiterated its 2025 revenue guidance of $72-76 million while anticipating a mid-single-digit percentage decline in third-quarter Surgical Glaucoma revenue year-over-year. The company is further pressured by risks such as increasing competition in minimally invasive glaucoma surgery (MIGS), slow advancements in insurance coverage for its TearCare product, and ongoing concerns about high quarterly cash burn rates. Additionally, while management has adjusted its operational expenditure guidance downward, the reduction may not sufficiently alleviate financial pressures given the external challenges faced by the company.

Sight Sciences (SGHT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sight Sciences (SGHT) Forecast

Analysts have given Sight Sciences (SGHT) a Buy based on their latest research and market trends.

According to 6 analysts, Sight Sciences (SGHT) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.02, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.02, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sight Sciences (SGHT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.